Three-Drug attack on rare blood cancer: custom treatment based on risk
NCT ID NCT07261163
Summary
This study is testing a combination of three medications (obinutuzumab, zanubrutinib, and lenalidomide) as the first treatment for adults with mantle cell lymphoma, a rare blood cancer. All 37 participants will receive the initial drug combination, then maintenance therapy tailored to their risk level—standard drugs for most, but CAR-T cell therapy followed by drugs for those at highest risk. The main goals are to see if this approach is feasible and effective at controlling the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.